enVVeno loses FDA appeal for VenoValve PMA; shifts focus to enVVe device

enVVeno Medical Corp

Unfavorable FDA appeal upheld not-approvable letter for VenoValve (received Aug 19, 2025).
Company to redirect resources to next-gen transcatheter valve enVVe, ready for human testing.
Cash and investments totaled $31.5M at Q3 end; quarterly burn $4-5M funds operations into 2027.
No approved treatments exist for severe deep CVI from valvular incompetence, affecting up to 3.5M US patients.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.